Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies - 12/08/11
Doi : 10.1016/j.jaad.2006.12.024
Gregory J. Fulchiero, MD, MSBioEng a, Heather Salvaggio, MD b, Joseph J. Drabick, MD c, Kevin Staveley-O’Carroll, MD d, Elizabeth M. Billingsley, MD a, James G. Marks, MD a, Klaus F. Helm, MD a, e, ⁎ 
a From the Department of Dermatology
b College of Medicine
c Department of Medicine
d Department of Surgery
e Department of Pathology, Milton S. Hershey Medical Center, Pennsylvania State University
Reprint requests: Klaus F. Helm, MD, Department of Dermatology, Milton S. Hershey Medical Center, Pennsylvania State University, 500 University Dr, HU-14, Hershey, PA 17033.Hershey, Pennsylvania
Abstract |
We report two cases of late recurrence of eruptive locoregional metastatic melanoma occurring 6 and 9 years after definitive surgical treatment. Each case (stage IB and IA) occurred after initiation of the subcutaneous anti-tumor necrosis factor medications etanercept and adalimumab, respectively. We discuss the association of immune suppression and melanoma. These cases illustrate a previously unrecognized and potentially causal relationship between tumor necrosis factor-⍺ inhibition and reactivation of latent melanoma.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Conflicts of interest: None declared. |
© 2007
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 56 - N° 5S
P. S65-S67 - mai 2007 Retour au numéro
Article précédent
- Table of contents
- Bullous pemphigoid associated with hypereosinophilic syndrome: Simultaneous response to imatinib
- Silke C. Hofmann, Kristin Technau, Antonia M.S. Müller, Michael Lübbert, Leena Bruckner-Tuderman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?